Q-omics provides the consensus-scored NME4 profile across patient tissues and cancer cell-line models. NME4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NME4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NME4 RNA expression shows 16,257 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where NME4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME4 survival associations across molecular data types. NME4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME4 RNA expression–survival associations across cancer types. High NME4 expression shows unfavorable associations in KIRC, UVM, SKCM, LUAD, CESC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NME4 RNA expression.
This table summarizes NME4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NME4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME4 shows higher tumor expression in KIRC, LUAD, LUSC, HNSC, COAD and BRCA. The KIRC box plot shows higher NME4 RNA expression in tumor versus normal tissue (log2 FC = +1.234, t-test p < 0.001).
This table shows molecular features associated with NME4 in patient tissues and cancer cell lines. In patient samples, NME4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NME4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
